Search over 3,000 reports

    Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2017

    Peripheral T-Cell Lymphomas (PTCL) - Pipeline Insights, 2017
    Date: Nov, 2017
    Type: Pharmaceutical Industry Report
    Pages: 115
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIPI0138
    DelveInsight's, "Peripheral T-Cell Lymphoma (PTCL)-Pipeline Insights, 2017", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Peripheral T-Cell Lymphoma (PTCL). This report provides information on the therapeutic development based on the Peripheral T-Cell Lymphoma (PTCL) dealing with all the pipeline drugs, comparative analysis at various stages covering Phase III, Phase II, and Phase I, IND filed therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the company's information involved in the therapeutic development of the products. It also features the discontinued and dormant products.
    The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
    Secondary sources information and data has been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations and available databases.
    Introduction
    Peripheral T-cell lymphoma (PTCL) Overview
    Pipeline Therapeutics
    Comparative Analysis
    Late Stage Products (Phase III)
    Mid Stage Products (Phase II)
    Early Stage Products (Phase I and IND)
    Therapeutic Assessment: Active Products
    Discontinued Products
    Dormant Products
    Analyst's Insights
    Companies Involved in Therapeutics Development
    Appendix
    Consulting Services
    About DelveInsight
    Contact Us
    Disclaimer
    Table 1: Total Products for Peripheral T cell Lymphoma
    Table 2: Late Stage Products (Phase III)
    Table 3: Mid Stage Products (Phase II)
    Table 4: Early Stage Products (Phase I and IND)
    Table 5: Assessment by Monotherapy Products
    Table 6: Assessment by Route of Administration
    Table 7: Assessment by Stage and Route of Administration
    Table 8: Assessment by Molecule Type
    Table 9: Assessment by Stage and Molecule Type
    Table 10: Discontinued Products
    Table 11: Discontinued Products
    Table 12: AB Science SA
    Table 13: arGEN X NV
    Table 14: Arno therapeutics
    Table 15: Bayer
    Table Continued?.
    Table 32: TG Therapeutics, Inc
    Figure 1: Total Products for Peripheral T cell Lymphoma
    Figure 2: Late Stage Products (Phase III)
    Figure 3: Mid Stage Products (Phase II)
    Figure 4: Early Stage Products (Phase I and IND)
    Figure 5: Assessment by Monotherapy
    Figure 6: Assessment by Route of Administration
    Figure 7: Assessment by Stage and Route of Administration
    Figure 8: Assessment by Molecule type
    Figure 9: Assessment by Stage and Molecule type
    Figure 10: Discontinued Products
    Figure 11: Discontinued Products
    Peripheral T-Cell Lymphomas (PTCL) Pipeline Drugs

    Peripheral T-Cell Lymphomas (PTCL) Pipeline Assessment

    Peripheral T-Cell Lymphomas (PTCL) Pipeline Analysis

    Peripheral T-Cell Lymphomas (PTCL) Drugs under Development

    Peripheral T-Cell Lymphomas (PTCL) Discovery drugs

    Peripheral T-Cell Lymphomas (PTCL) Preclinical drugs

    Peripheral T-Cell Lymphomas (PTCL) Phase I drugs

    Peripheral T-Cell Lymphomas (PTCL) Phase II drugs

    Peripheral T-Cell Lymphomas (PTCL) Phase III Pipeline Drugs Assessment

    Peripheral T-Cell Lymphomas (PTCL) Preregistration drugs

    Peripheral T-Cell Lymphomas (PTCL) Molecules in pipeline

    • Single User License
      (20% Off)
      $1,250.00
      $1000
    • Site License
      (30% Off)
      $2,500.00
      $1750
    • Global License
      (40% Off)
      $4,000.00
      $2400

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap